The limitations of treatment options in bloodstream infections caused by multidrug-resistant Acinetobacter baumannii (MDRAB) have been related to high morbidity and mortality. The aim of our present study was to determine antimicrobial susceptibility profiles, molecular resistance patterns, and biofilm properties of A. baumannii isolated from bloodstream infections.
Materials and Methods:
In the present study, a total of 44 A. baumannii bloodstream isolates were included. Antimicrobial susceptibility profiles and biofilm formation ability were assessed. The distribution of class D carbapenemases, ISAba1, ISAba1/blaOXA-23, blaNDM-1, mcr-1, and ompA was investigated by polymerase chain reaction (PCR). Arbitrarily primed-PCR (AP-PCR) was performed to evaluate clonal relationships.
Results:
A total of 32 isolates were MDRAB, whereas 6 isolates were also resistant to colistin without mcr-1 positivity. All isolates were harboring blaOXA-51 gene, whereas blaOXA-23 positivity was 63.6%. Fifty percent of the isolates had ISAba1. ISAba1 upstream of blaOXA-23 was determined in 18 isolates. None of the isolates were positive for blaNDM-1 gene. Majority of the strains were strong biofilm producers (86.8%). A total of 56.8% of the isolates were positive for ompA gene with no direct association with strong biofilm formation. However, blaOXA-51 + 23 genotype and trimethoprim–sulfamethoxazole resistance showed a significant relationship with biofilm formation. AP-PCR analysis revealed six distinct clusters of A. baumannii.
Conclusions:
Herein, majority of the A. baumannii blood isolates were characterized as blaOXA-51+OXA-23 carbapenemase genotype and were strong biofilm formers. None of the isolates were positive for blaNDM-1, which was promising. Resistant isolates were tended to form strong biofilms. Our results highlight the emergence of oxacillinase-producing MDRAB isolated from bloodstream with high biofilm formation ability.
Get full access to this article
View all access options for this article.
References
1.
Almasaudi, S.B. 2018. Acinetobacter spp. as nosocomial pathogens: epidemiology and resistance features. Saud. J. Biol. Sci. 25:586–596.
2.
SmolyakovR., BorerA., RiesenbergK., SchlaefferF., AlkanM., PorathA., RimarD., AlmogY., and GiladJ.. 2003. Nosocomial multi-drug resistant Acinetobacter baumannii bloodstream infection: risk factors and outcome with ampicillin-sulbactam treatment. J. Hosp. Infect. 54:32–38.
3.
Garnacho-MonteroJ., Amaya-VillarR., Ferrandiz-MillonC., Diaz-MartinA., Lopez-SanchezJ.M, and Gutierrez-PizarrayaA.. 2015. Optimum treatment strategies for carbapenem-resistant Acinetobacter baumannii bacteremia. Expert Rev. Anti Infect. Ther. 13:769–777.
4.
MagiorakosA.P., SrinivasanA., CareyR.B, CarmeliY., FalagasM.E, GiskeC.G, HarbarthS., HindlerJ.F, KahlmeterG., Olsson-LiljequistB., PatersonD.L, RiceL.B, StellingJ., StruelensM.J, VatopoulosA., WeberJ.T, and MonnetD.L.. 2012. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect. 18:268–281.
5.
ClarkN.M., ZhanelG.G, and LynchJ.P, 3rd. 2016. Emergence of antimicrobial resistance among Acinetobacter species: a global threat. Curr. Opin. Crit. Care, 22:491–499.
6.
TurtonJ.F., WardM.E, WoodfordN., KaufmannM.E, PikeR., LivermoreD.M, and PittT.L.. 2006. The role of ISAba1 in expression of OXA carbapenemase genes in Acinetobacter baumannii. FEMS Microbiol. Lett. 258:72–77.
7.
VianaG.F., ZagoM.C, MoreiraR.R, ZarpellonM.N, MenegucciT.C, CardosoC.L, and TognimM.C.. 2016. ISAba1/blaOXA-23: a serious obstacle to controlling the spread and treatment of Acinetobacter baumannii strains. Am. J. Infect. Control, 44:593–595.
8.
MeshkatZ., AminiY., SadeghianH., and SalimizandH.. 2019. ISAba1/blaOXA-23-like family is the predominant cause of carbapenem resistance in Acinetobacter baumannii and Acinetobacter nosocomialis in Iran. Infect. Genet. Evol. 71:60–66.
9.
BardbariA.M., ArabestaniM.R, KaramiM., KeramatF., AlikhaniM.Y, and BagheriK.P.. 2017. Correlation between ability of biofilm formation with their responsible genes and MDR patterns in clinical and environmental Acinetobacter baumannii isolates. Microb. Pathog. 108:122–128.
10.
GaddyJ.A., TomarasA.P, and ActisL.A.. 2009. The Acinetobacter baumannii 19606 OmpA protein plays a role in biofilm formation on abiotic surfaces and in the interaction of this pathogen with eukaryotic cells. Infect. Immun. 77:3150–3160.
11.
ChoiC.H., HyunS.H, LeeJ.Y, LeeJ.S, LeeY.S, KimS.A, ChaeJ.P, YooS.M, and LeeJ.C.. 2008. Acinetobacter baumannii outer membrane protein A targets the nucleus and induces cytotoxicity. Cell Microbiol. 10:309–319.
12.
Sanchez-EncinalesV., Alvarez-MarinR., Pachon-IbanezM.E, Fernandez-CuencaF., PascualA., Garnacho-MonteroJ., Martinez-MartinezL., VilaJ., TomasM.M, CisnerosJ.M, BouG., Rodriguez-BanoJ., PachonJ., and SmaniY.. 2017. Overproduction of outer membrane protein A by Acinetobacter baumannii as a risk factor for nosocomial pneumonia, bacteremia, and mortality rate increase. J. Infect. Dis. 215:966–974.
13.
Clinical and Laboratory Standards Institute [CLSI]. 2006. Performance Standards for Antimicrobial Disk Susceptibility Tests. Approved Standard. 9th ed. M2–A9. CLSI, Wayne, PA.
HouC., and YangF.. 2015. Drug-resistant gene of blaOXA-23, blaOXA-24, blaOXA-51 and blaOXA-58 in Acinetobacter baumannii. Int. J. Clin. Exp. Med. 8:13859–13863.
16.
NordmannP., PoirelL., CarrerA., TolemanM.A, and WalshT.R.. 2011. How to detect NDM-1 producers. J. Clin. Microbiol. 49:718–721.
17.
RebeloA.R., BortolaiaV., KjeldgaardJ.S, PedersenS.K, LeekitcharoenphonP., HansenI.M, GuerraB., MalornyB., BorowiakM., HammerlJ.A, BattistiA., FrancoA., AlbaP., Perrin-GuyomardA., GranierS.A, EscobarC.D.F, Malhotra-KumarS., VillaL., CarattoliA., and HendriksenR.S.. 2018. Multiplex PCR for detection of plasmid-mediated colistin resistance determinants, mcr-1, mcr-2, mcr-3, mcr-4 and mcr-5 for surveillance purposes. Euro Surveill. 23:17-00672.
18.
SegalH., GarnyS., and ElishaB.G.. 2005. Is IS(ABA-1) customized for Acinetobacter? FEMS Microbiol. Lett. 243:425–429.
19.
HongS.B., ShinK.S, HaJ., and HanK.. 2013. Co-existence of blaOXA-23 and armA in multidrug-resistant Acinetobacter baumannii isolated from a hospital in South Korea. J. Med. Microbiol. 62:836–844.
20.
RoyerS., de CamposP.A, AraujoB.F, FerreiraM.L, GoncalvesI.R, BatistaoD., BrigidoR., CerdeiraL.T, MachadoL.G, de BritoC.S, Gontijo-FilhoP.P, and RibasR.M.. 2018. Molecular characterization and clonal dynamics of nosocomial blaOXA-23 producing XDR Acinetobacter baumannii. PLoS One, 13:e0198643.
21.
HandalR., QunibiL., SahouriI., JuhariM., DawodiR., MarzouqaH., and HindiyehM.. 2017. Characterization of Carbapenem-Resistant Acinetobacter baumannii Strains Isolated from Hospitalized Patients in Palestine. Int. J. Microbiol. 2017:8012104.
22.
StepanovicS., VukovicD., DakicI., SavicB., and Svabic-VlahovicM.. 2000. A modified microtiter-plate test for quantification of staphylococcal biofilm formation. J. Microbiol. Methods, 40:175–179.
23.
WelshJ., and McClellandM.. 1990. Fingerprinting genomes using PCR with arbitrary primers. Nucleic Acids Res. 18:7213–7218.
24.
HerasJ., DominguezC., MataE., PascualV., LozanoC., TorresC., and ZarazagaM.. 2015. GelJ—a tool for analyzing DNA fingerprint gel images. BMC Bioinformatics, 16:270.
25.
HowardA., O'DonoghueM., FeeneyA., and SleatorR.D.. 2012. Acinetobacter baumannii: an emerging opportunistic pathogen. Virulence, 3:243–250.
26.
LiS., DuanX., PengY., and RuiY.. 2019. Molecular characteristics of carbapenem-resistant Acinetobacter spp. from clinical infection samples and fecal survey samples in Southern China. BMC Infect. Dis. 19:900.
27.
AsginN., OtluB., CakmakliogullariE.K, and CelikB.. 2019. High prevalence of TEM, VIM, and OXA-2 beta-lactamases and clonal diversity among Acinetobacter baumannii isolates in Turkey. J. Infect. Dev. Ctries. 13:794–801.
28.
FalagasM.E., and KasiakouS.K.. 2005. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin. Infect. Dis. 40:1333–1341.
29.
KocakC.O., and HazirolanG.. 2019. Colistin resistance in carbapenem-resistant Klebsiella pneumoniae clinical isolates. Turk. Mikrobiyoloji Cem. Derg. 49:17–23.
30.
CaponeA., GiannellaM., FortiniD., GiordanoA., MeledandriM., BallardiniM., VendittiM., BordiE., CapozziD., BaliceM.P, TarasiA., ParisiG., LappaA., CarattoliA., and PetrosilloN.. 2013. High rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality. Clin. Microbiol. Infect. 19:E23–E30.
31.
JuhaszE., IvanM., PinterE., PongraczJ., and KristofK.. 2017. Colistin resistance among blood culture isolates at a tertiary care centre in Hungary. J. Glob. Antimicrob. Resist. 11:167–170.
32.
PapathanakosG., AndrianopoulosI., PapathanasiouA., PriavaliE., KoulentiD., and KoulourasV.. 2020. Colistin-resistant Acinetobacter baumannii bacteremia: a serious threat for critically ill patients. Microorganisms, 8:287.
33.
AdamsM.D., NickelG.C, BajaksouzianS., LavenderH., MurthyA.R, JacobsM.R, and BonomoR.A.. 2009. Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system. Antimicrob. Agents Chemother. 53:3628–3634.
34.
LinM.F., LinY.Y, and LanC.Y.. 2017. Contribution of EmrAB efflux pumps to colistin resistance in Acinetobacter baumannii. J. Microbiol. 55:130–136.
35.
MoffattJ.H., HarperM., HarrisonP., HaleJ.D, VinogradovE., SeemannT., HenryR., CraneB., St MichaelF., A.D. CoxB, Adler, NationR.L, LiJ., BoyceJ.D. 2010. Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production. Antimicrob. Agents Chemother. 54:4971–4977.
36.
ZarrilliR., GiannouliM., TomasoneF., TriassiM., and TsakrisA.. 2009. Carbapenem resistance in Acinetobacter baumannii: the molecular epidemic features of an emerging problem in health care facilities. J. Infect. Dev. Ctries. 3:335–341.
37.
WangT.H., LeuY.S, WangN.Y, LiuC.P, and YanT.R.. 2018. Prevalence of different carbapenemase genes among carbapenem-resistant Acinetobacter baumannii blood isolates in Taiwan. Antimicrob. Resist. Infect. Control, 7:123.
38.
BoralB., UnaldiO., ErginA., DurmazR., Eser; and Acinetobacter Study GroupO.K. 2019. A prospective multicenter study on the evaluation of antimicrobial resistance and molecular epidemiology of multidrug-resistant Acinetobacter baumannii infections in intensive care units with clinical and environmental features. Ann. Clin. Microbiol. Antimicrob. 18:19.
39.
Avila-NovoaM.G., Solis-VelazquezO.A, Rangel-LopezD.E, Gonzalez-GomezJ.P, Guerrero-MedinaP.J, and Gutierrez-LomeliM.. 2019. Biofilm formation and detection of fluoroquinolone- and carbapenem-resistant genes in multidrug-resistant Acinetobacter baumannii. Can. J. Infect. Dis. Med. Microbiol. 2019:3454907.
40.
KobsV.C., FerreiraJ.A, BobrowiczT.A, FerreiraL.E, DeglmannR.C, WestphalG.A, and FrancaP.H.. 2016. The role of the genetic elements bla oxa and IS Aba 1 in the Acinetobacter calcoaceticus-Acinetobacter baumannii complex in carbapenem resistance in the hospital setting. Rev. Soc. Bras. Med. Trop. 49:433–440.
41.
VillalonP., ValdezateS., Medina-PascualM.J, RubioV., VindelA., and Saez-NietoJ.A.. 2011. Clonal diversity of nosocomial epidemic Acinetobacter baumannii strains isolated in Spain. J. Clin. Microbiol. 49:875–882.
42.
EzeE.C., CheniaH.Y, and El ZowalatyM.E.. 2018. Acinetobacter baumannii biofilms: effects of physicochemical factors, virulence, antibiotic resistance determinants, gene regulation, and future antimicrobial treatments. Infect. Drug Resist. 11:2277–2299.
43.
QiL., LiH., ZhangC., LiangB., LiJ., WangL., DuX., LiuX., QiuS., and SongH.. 2016. Relationship between antibiotic resistance, biofilm formation, and biofilm-specific resistance in Acinetobacter baumannii. Front. Microbiol. 7:483.
44.
YangC.H., SuP.W, MoiS.H, and ChuangL.Y.. 2019. Biofilm formation in Acinetobacter baumannii: genotype-phenotype correlation. Molecules, 24:1849.
45.
TomarasA.P., DorseyC.W, EdelmannR.E, and ActisL.A.. 2003. Attachment to and biofilm formation on abiotic surfaces by Acinetobacter baumannii: involvement of a novel chaperone-usher pili assembly system. Microbiology, 149:3473–3484.
46.
GurungJ., KhyriemA.B, BanikA., LyngdohW.V, ChoudhuryB., and BhattacharyyaP.. 2013. Association of biofilm production with multidrug resistance among clinical isolates of Acinetobacter baumannii and Pseudomonas aeruginosa from intensive care unit. Indian J. Crit. Care Med. 17:214–218.
47.
AminM., NavidifarT., ShooshtariF.S, RashnoM., SavariM., JahangirmehrF., and ArshadiM.. 2019. Association between biofilm formation, structure, and the expression levels of genes related to biofilm formation and biofilm-specific resistance of Acinetobacter baumannii strains isolated from burn infection in Ahvaz, Iran. Infect. Drug Resist. 12:3867–3881.
48.
Perez, L.R. 2015. Acinetobacter baumannii displays inverse relationship between meropenem resistance and biofilm production. J. Chemother. 27:13–16.
49.
WangY.C., HuangT.W, YangY.S, KuoS.C, ChenC.T, LiuC.P, LiuY.M, ChenT.L, ChangF.Y, WuS.H, HowC.K, and LeeY.T.. 2018. Biofilm formation is not associated with worse outcome in Acinetobacter baumannii bacteraemic pneumonia. Sci. Rep. 8:7289.
50.
Da CundaP., IribarnegarayV., Papa-EzdraR., BadoI., GonzalezM.J, ZuninoP., VignoliR., and ScavoneP.. 2020. Characterization of the different stages of biofilm formation and antibiotic susceptibility in a clinical Acinetobacter baumannii strain. Microb. Drug Resist. 26:569–575.
51.
VijayakumarS., RajenderanS., LaishramS., AnandanS., BalajiV., and BiswasI.. 2016. Biofilm formation and motility depend on the nature of the Acinetobacter baumannii clinical isolates. Front. Public Health, 4:105.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
